309 related articles for article (PubMed ID: 18207114)
21. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
Banzo I; Jiménez-Bonilla J; Ortega-Nava F; Quirce R; Martínez-Rodríguez I; de Arcocha-Torres M; Rodríguez E; Vázquez JL; Sánchez PJ; Martínez-Amador N; Ibañez-Bravo S; Carril JM
Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
[TBL] [Abstract][Full Text] [Related]
22. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
23. PET of brain amyloid and tau in mild cognitive impairment.
Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990
[TBL] [Abstract][Full Text] [Related]
24. Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias.
Scheltens P; Korf ES
Curr Opin Neurol; 2000 Aug; 13(4):391-6. PubMed ID: 10970055
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
26. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.
Small GW; Siddarth P; Burggren AC; Kepe V; Ercoli LM; Miller KJ; Lavretsky H; Thompson PM; Cole GM; Huang SC; Phelps ME; Bookheimer SY; Barrio JR
Arch Gen Psychiatry; 2009 Jan; 66(1):81-7. PubMed ID: 19124691
[TBL] [Abstract][Full Text] [Related]
27. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
28. A critical discussion of the role of neuroimaging in mild cognitive impairment.
Wolf H; Jelic V; Gertz HJ; Nordberg A; Julin P; Wahlund LO
Acta Neurol Scand Suppl; 2003; 179():52-76. PubMed ID: 12603252
[TBL] [Abstract][Full Text] [Related]
29. Multiparametric magnetic resonance imaging and positron emission tomography findings in neurodegenerative diseases: Current status and future directions.
Soni N; Ora M; Bathla G; Nagaraj C; Boles Ponto LL; Graham MM; Saini J; Menda Y
Neuroradiol J; 2021 Aug; 34(4):263-288. PubMed ID: 33666110
[TBL] [Abstract][Full Text] [Related]
30. MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
Banerjee G; Kim HJ; Fox Z; Jäger HR; Wilson D; Charidimou A; Na HK; Na DL; Seo SW; Werring DJ
Brain; 2017 Apr; 140(4):1107-1116. PubMed ID: 28335021
[TBL] [Abstract][Full Text] [Related]
31. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.
Lowe VJ; Lundt ES; Albertson SM; Przybelski SA; Senjem ML; Parisi JE; Kantarci K; Boeve B; Jones DT; Knopman D; Jack CR; Dickson DW; Petersen RC; Murray ME
Alzheimers Dement; 2019 Jul; 15(7):927-939. PubMed ID: 31175025
[TBL] [Abstract][Full Text] [Related]
32. Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography.
Yokoyama S; Kajiya Y; Yoshinaga T; Tani A; Hirano H
Psychogeriatrics; 2014 Jun; 14(2):110-7. PubMed ID: 24954834
[TBL] [Abstract][Full Text] [Related]
33. Neurological update: neuroimaging in dementia.
Rittman T
J Neurol; 2020 Nov; 267(11):3429-3435. PubMed ID: 32638104
[TBL] [Abstract][Full Text] [Related]
34. [Neuroimaging in dementia].
Lehéricy S; Delmaire C; Galanaud D; Dormont D
Presse Med; 2007 Oct; 36(10 Pt 2):1453-63. PubMed ID: 17611066
[TBL] [Abstract][Full Text] [Related]
35. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
[TBL] [Abstract][Full Text] [Related]
36. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
37. Genetic and degenerative disorders primarily causing dementia.
Masdeu JC; Pascual B
Handb Clin Neurol; 2016; 135():525-564. PubMed ID: 27432682
[TBL] [Abstract][Full Text] [Related]
38. Neuroimaging for diagnosis of dementia.
Small GW; Leiter F
J Clin Psychiatry; 1998; 59 Suppl 11():4-7. PubMed ID: 9731543
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of early-phase [
Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index.
Döbert N; Pantel J; Frölich L; Hamscho N; Menzel C; Grünwald F
Dement Geriatr Cogn Disord; 2005; 20(2-3):63-70. PubMed ID: 15908747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
